Document is current
Any future updates will be listed below
-
Authors
Naidoo, Jarushka https://orcid.org/0000-0002-3470-8686
Schreck, Karisa C
Fu, Wei
Hu, Chen
Carvajal-Gonzalez, Alexander
Connolly, Roisin M
Santa-Maria, Cesar A
Lipson, Evan J https://orcid.org/0000-0003-2976-0911
Holdhoff, Matthias https://orcid.org/0000-0002-3285-3484
Forde, Patrick M
Douville, Christopher
Riemer, Joanne
Barnes, Amanda
Redmond, Kristin J
Kleinberg, Lawrence
Page, Brandi
Aygun, Nafi
Kinzler, Kenneth W
Papadopoulos, Nickolas
Bettegowda, Chetan
Venkatesan, Arun
Brahmer, Julie R
Grossman, Stuart A
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03091478 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
https://doi.org/10.1136/jitc-2021-002473
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
-
Funding
Funding for this research was provided by:
Merck Sharp and Dohme
National Cancer Institute (NIH RA37CA230400)
National Cancer Institute (U01CA230691)
- License Information
